# Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

> **NCT03356834** · PHASE4 · COMPLETED · sponsor: **Humanity and Health Research Centre** · enrollment: 575 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir alafenamide(TAF)
- **DRUG:** Tenofovir disoproxil fumarate(TDF)

## Key facts

- **NCT ID:** NCT03356834
- **Lead sponsor:** Humanity and Health Research Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 575 (ACTUAL)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356834, "Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03356834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*